Polymerase chain reaction

NuProbe Announces New Research and New Product on DNA Microsatellite Instability

Monday, July 26, 2021 - 5:00pm

Simultaneously, the company announced the release of the VarTrace MSI qPCR research use only assay for detection of DNA microsatellite instability (MSI) from tissue or blood specimens.

Key Points: 
  • Simultaneously, the company announced the release of the VarTrace MSI qPCR research use only assay for detection of DNA microsatellite instability (MSI) from tissue or blood specimens.
  • By constructing and experimentally validating a thermodynamic model of DNA microsatellite binding, NuProbe scientists overcame the challenges associated with MSI detection.
  • "The NuProbe VarTrace MSI qPCR assay allows qPCR-based detection of MSI from tumor tissue and cell-free DNA," said Alessandro Pinto, Ph.D., Associate Director of Product at NuProbe USA.
  • This allows the NuProbe product to be applied to cell-free DNA from peripheral blood plasma as well as to formalin-fixed, paraffin-embedded (FFPE) tumor tissue.

Therma Bright Awaits FDA-EUA Approval From Over 260 AcuVid(TM) Clinical Study Test Results

Thursday, July 22, 2021 - 2:24pm

Negative percent agreement (NPA) is the proportion of comparative/reference method negative results in which the test method result is negative.

Key Points: 
  • Negative percent agreement (NPA) is the proportion of comparative/reference method negative results in which the test method result is negative.
  • "We're excited to share our overall 264 test results from our Brazilian AcuVid Saliva / RT-PCR Test Clinical Study.
  • The additional 201 test results, on top of the initial 63, not only exceed FDA-EUA minimum requirements, but confirms the performance quality and ease-of-use of our AcuVid saliva test.
  • In fact, our complete AcuVid study achieved comparable, and in some cases, better performance results than other leading COVID-19 rapid antigen tests available on today's market," expressed Rob Fia, CEO of Therma Bright.

Global PCR and Realtime PCR Testing Market Forecast to Decline at a CAGR of -10.93% from 2020 to reach $12,546.83 Million in 2025 - ResearchAndMarkets.com

Thursday, July 22, 2021 - 11:06am

The global polymerase chain reaction (PCR) and real-time polymerase chain reaction (PCR) testing market reached a value of nearly $22,380 million in 2020, having increasing at a compound annual growth rate (CAGR) of 28.11% since 2015.

Key Points: 
  • The global polymerase chain reaction (PCR) and real-time polymerase chain reaction (PCR) testing market reached a value of nearly $22,380 million in 2020, having increasing at a compound annual growth rate (CAGR) of 28.11% since 2015.
  • The global polymerase chain reaction (PCR) and real-time polymerase chain reaction (PCR) testing market is expected to stabilize and reach $17,054.69 million in 2030, at a CAGR of 6.33%.
  • North America was the largest region in the global polymerase chain reaction (PCR) and real-time polymerase chain reaction (PCR) testing market, accounting for 34.5% of the total in 2020.
  • The polymerase chain reaction (PCR) and real-time polymerase chain reaction (PCR) testing market size will decline the least in Indonesia at $85.8 million.

New Coronavirus Testing Protocol Could Help Labs Keep Up With Rising Testing Demands as Delta Variant Spreads

Wednesday, July 21, 2021 - 7:21pm

This protocol could play a vital role in helping labs keep up with coronavirus testing demands as the Delta variant fuels a new increase in COVID-19 cases around the world.

Key Points: 
  • This protocol could play a vital role in helping labs keep up with coronavirus testing demands as the Delta variant fuels a new increase in COVID-19 cases around the world.
  • Many resource-limited countries are still struggling to secure coronavirus vaccines, while in the U.S., vaccine hesitancy is hindering efforts to achieve herd immunity.
  • Typically, PCR coronavirus testing involves the extraction of viral genetic material from nasopharyngeal patient specimens transported in viral media.
  • In general, SwabExpress is much easier to perform than the standard PCR coronavirus testing protocol.

Applied Food Diagnostics announces the first reporter-labeled Total QC diagnostic line for food pathogens

Tuesday, July 20, 2021 - 3:26pm

BLOOMSBURG, Pa., July 20, 2021 /PRNewswire/ -- Applied Food Diagnostics, Inc. , The World's Most Innovative Microbiology Lab Solutions Company, is pleased to announce a new qPCR diagnostic product line.

Key Points: 
  • BLOOMSBURG, Pa., July 20, 2021 /PRNewswire/ -- Applied Food Diagnostics, Inc. , The World's Most Innovative Microbiology Lab Solutions Company, is pleased to announce a new qPCR diagnostic product line.
  • AFD's breakthrough Total QC-qPCR line of test kits simultaneously detects the target food pathogens along with the reporter-labeled quality control strain, such as Green Fluorescent Protein.
  • Many food pathogen laboratories currently use Green Fluorescent Protein (GFP) tagged positive quality control strains.
  • Applied Food Diagnostics, Inc. (AFD) develops and manufactures sampling and testing products specifically for the food centric sectors.

Visby Medical Makes Strategic Hires to Continue Business Development

Monday, July 19, 2021 - 4:09pm

SAN JOSE, Calif., July 19, 2021 /PRNewswire/ --Today, Visby Medical , a leading medical diagnostic company, announced three strategic new hires Mark Ibison as Chief Financial Officer, Christopher J. Jowett as Chief Commercial Officer and Alicia Zuiker as Chief People Officer.

Key Points: 
  • SAN JOSE, Calif., July 19, 2021 /PRNewswire/ --Today, Visby Medical , a leading medical diagnostic company, announced three strategic new hires Mark Ibison as Chief Financial Officer, Christopher J. Jowett as Chief Commercial Officer and Alicia Zuiker as Chief People Officer.
  • "In the last year, Visby Medical has seen exponential growth with our innovative PCR technology," said Adam de la Zerda, CEO of Visby Medical.
  • Mark joins Visby Medical from Mesa Biotech with vast experience developing effective financial models to drive performance improvements.
  • Visby Medical has been working to change the order of diagnosis and treatment of infectious disease for a decade.

Mirimus, Inc. Announces Publication of Research in The Lancet-Affiliated Journal EClinicalMedicine Discussing Pooled, Saliva-Based COVID-19 Testing as Efficient, Affordable Surveillance Approach for K-12 Schools

Monday, July 19, 2021 - 1:01pm

The SalivaClear platform provides an efficient and affordable alternative to individual PCR testing.

Key Points: 
  • The SalivaClear platform provides an efficient and affordable alternative to individual PCR testing.
  • As a result, all schools utilizing the SalivaClear testing platform in this study, remained open to in-person learning.
  • The data also demonstrated that pooling saliva samples substantially reduced the cost associated with PCR testing.
  • The research also evaluated the cost of the initial pooled testing, which averaged $10 (range: $8-$12) per individual for all participating schools.

Bionano’s Optical Genome Mapping Reveals New Insights and Prognostic Capabilities Compared to Traditional Cytogenetics Techniques in Several Leukemia Clinical Research Studies Presented at the ECA

Wednesday, July 14, 2021 - 1:00pm

SAN DIEGO, July 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced optical genome mapping (OGM) reveals new insights and prognostic capabilities compared to traditional cytogenetics techniques in several leukemia clinical research studies presented at the 2021 European Cytogenomics Conference (ECA).

Key Points: 
  • SAN DIEGO, July 14, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced optical genome mapping (OGM) reveals new insights and prognostic capabilities compared to traditional cytogenetics techniques in several leukemia clinical research studies presented at the 2021 European Cytogenomics Conference (ECA).
  • In this study, 34 pediatric leukemias (26 ALL and 8 AML) were analyzed by OGM relative to traditional cytogenetics techniques (karyotyping, FISH, and PCR).
  • This study is the basis of validation and accreditation of an assay to be used onsite in their lab.
  • In 45% of cases, OGM provided additional information, orthogonally confirmed, demonstrating an improvement in diagnostic potential relative to traditional cytogenetics techniques.

Capillary Electrophoresis Market|COVID-19 Impact Analysis|Technavio

Tuesday, July 13, 2021 - 11:30pm

The capillary electrophoresis market is poised to grow by USD 248.09 million during 2021-2025, progressing at a CAGR of 5.85% during the forecast period.

Key Points: 
  • The capillary electrophoresis market is poised to grow by USD 248.09 million during 2021-2025, progressing at a CAGR of 5.85% during the forecast period.
  • The report on the capillary electrophoresis market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
  • The capillary electrophoresis market analysis includes end-user and geography landscape segments.
  • This study identifies the rising prevalence of chronic conditions as one of the prime reasons driving the capillary electrophoresis market growth during the next few years.

Pandemic Response Lab and Brio Announce Partnership to Provide Innovative Molecular Diagnostics Testing Solutions for the Entertainment Industry

Tuesday, July 13, 2021 - 5:09pm

The Pandemic Response Lab (PRL) and Brio today announced they are partnering to provide COVID-19 testing and variant zone surveillance tracking to mitigate the risk of new and emerging variants for the entertainment industry.

Key Points: 
  • The Pandemic Response Lab (PRL) and Brio today announced they are partnering to provide COVID-19 testing and variant zone surveillance tracking to mitigate the risk of new and emerging variants for the entertainment industry.
  • The partnership will deliver fast, low-cost, end-to-end testing solutions to help ensure the safety of cast and crew members while reducing costs and production downtime.
  • PRL, operated by Opentrons Labworks, Inc. , will conduct the back-end lab work (laboratory diagnostics), including gold-standard PCR testing and genome sequencing of all positive results to track variants.
  • "PRL NYC's vertically integrated approach to lab testing is akin to what has made SpaceX so disruptive to the aerospace industry that makes this already productive partnership even more exciting for us."